# CeriBell Inc. (CBLL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $24.72, market value $949 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). CeriBell Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 9.3×**. Each dollar of revenue is priced at 9.3×.
- **Price / book: 7.4×**. The shares trade at 7.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -5.8%** (5-yr avg -8.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 88.9%**. CeriBell Inc. keeps 88.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -68.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -60.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -34.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -33.7%**. Each dollar of assets produces -33.7% of profit.

## Growth
- **Revenue growth (1 yr): 36.1%**. Revenue grew 36.1% over the last year.
- **EPS growth (1 yr): 56.9%**. Earnings per share rose 56.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 9.73** (quick 9.73). Current assets cover the next year's liabilities 9.73 times.
- **Altman Z-score: 15.67**. A Z-score of 15.67 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. CeriBell Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover CeriBell Inc.; the consensus is strong_buy, with an average price target of $27.29 (+10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 100.5%** (YTD 12.7%, 3-mo 35.5%). The shares are up 100.5% over twelve months including dividends.
- **From 52-week high: -2.4%** (127.8% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 70**. An RSI of 70 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 1.20** (volatility 52%). Beta of 1.20 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CBLL · Page: https://foliofundamentals.com/stocks/cbll

Not investment advice.